论文部分内容阅读
目的观察优泌乐25和优泌林70/30在2型糖尿病中的疗效与安全性比较,指导2型糖尿病患者治疗和用药。方法 160例口服药失效的2型糖尿病患者随机分成治疗组和对照组,各80例,分别给予优泌乐25和优泌林70/30并观察12周。结果两组空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb A1C)均下降,治疗组效果好于对照组,差异有统计学意义(P<0.05)。治疗过程中治疗组低血糖发生率6.25%;对照组低血糖发生率为17.50%,治疗组低血糖发生率明显低于对照组(χ2=4.838,P=0.028)。结论优泌乐25能更有效控制空腹、餐后2 h血糖和糖化血红蛋白,降低低血糖发生率,且疗效、依从性和安全性优于优泌林70/30,值得在2型糖尿病患者中推广。
Objective To observe the efficacy and safety of Uehara 25 and Uehara 50/30 in type 2 diabetes and to guide the treatment and medication of type 2 diabetes patients. Methods A total of 160 patients with type 2 diabetes who failed oral administration were randomly divided into treatment group and control group, with 80 cases in each group. Results The fasting blood glucose (FBG), 2 h postprandial blood glucose (2 h PG) and Hb A1C in both groups decreased. The treatment group was better than the control group (P <0.05). The incidence of hypoglycemia in the treatment group was 6.25%. The incidence of hypoglycemia in the control group was 17.50%. The incidence of hypoglycemia in the treatment group was significantly lower than that in the control group (χ2 = 4.838, P = 0.028). Conclusion Youxuelu 25 can more effectively control fasting, postprandial 2h blood glucose and glycosylated hemoglobin, reduce the incidence of hypoglycemia, and efficacy, compliance and safety superior to youngetal 70/30, it is worth in patients with type 2 diabetes Promotion.